{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:00:18Z","timestamp":1761919218569},"reference-count":33,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2009,3,12]],"date-time":"2009-03-12T00:00:00Z","timestamp":1236816000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Birth Defects Research Pt B"],"published-print":{"date-parts":[[2009,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>BACKGROUND<\/jats:bold>: Natalizumab is a humanized monoclonal IgG4 antibody to human \u03b14 integrin that blocks the interaction of \u03b14\u03b21 and \u03b14\u03b27 integrins with their ligands, including fibronectin, vascular cell adhesion molecule\u20101, and mucosal addressin cellular adhesion molecule\u20101. Because \u03b14 integrins and their ligands are widely involved in mammalian development, lymphopoeisis, and hematopoiesis, natalizumab may interfere with these processes. <jats:bold>METHODS<\/jats:bold>: The effects of prenatal exposure to natalizumab on postnatal development were assessed in cynomolgus monkeys at doses of 0 and 30\u2009mg\/kg administered intravenously every other day from gestational day (GD) 20 to 70 or GD 20 to term. Infants were delivered by natural birth and evaluated for general health, survival, development, and immunological structure and function at 12 or 18 months. <jats:bold>RESULTS<\/jats:bold>: An increase in abortions was seen in the first cohort of natalizumab\u2010treated dams (39.3 vs. 7.1% in the controls) but not in the second cohort (33.3, 37.5%). Infants in the term treatment group had elevated lymphocyte (\u223c150%) and nucleated red blood cell counts (\u223c400%), consistent with the pharmacological effect of natalizumab, and reductions in platelet counts (\u223c28%), which were reversible following clearance of natalizumab. No anemia was observed. Infants in the term treatment group had significantly increased spleen weights at 12 months but not at 18 months. All other experimental observations in infants from natalizumab\u2010treated dams were comparable with those of controls. <jats:bold>CONCLUSION<\/jats:bold>: Natalizumab had no adverse effects on the general health, survival, development, or immunological structure and function of infants born to dams treated with natalizumab during pregnancy. <jats:italic>Birth Defects Res (Part B)<\/jats:italic> 86: 144\u2010156, 2009. \u00a9 2009 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/bdrb.20193","type":"journal-article","created":{"date-parts":[[2009,3,12]],"date-time":"2009-03-12T19:06:55Z","timestamp":1236884815000},"page":"144-156","source":"Crossref","is-referenced-by-count":50,"title":["Postnatal development in cynomolgus monkeys following prenatal exposure to natalizumab, an \u03b14 integrin inhibitor"],"prefix":"10.1002","volume":"86","author":[{"given":"Nancy G.","family":"Wehner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Shopp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrid","family":"Osterburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antje","family":"Fuchs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eberhard","family":"Buse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,3,12]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)81301-X"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.2307\/2983644"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.189.9.1467"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdrb.20001"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2005.03.013"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1177\/0192623308326095"},{"key":"e_1_2_6_8_1","first-page":"111","volume-title":"Handbook of developmental toxicology","author":"DeSesso JM","year":"1997"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.2307\/2528490"},{"key":"e_1_2_6_10_1","first-page":"205","article-title":"Maternal factors affecting reproduction in a breeding colony of cynomolgus macaques (Macaca fascicularis)","volume":"39","author":"Gardin JF","year":"1989","journal-title":"Lab Anim Sci"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1101\/gad.9.1.1"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdrb.20023"},{"key":"e_1_2_6_13_1","first-page":"4","article-title":"Infant mortality in Macaca mulatta: neonatal and post\u2010neonatal mortality at the California Primate Research Center, 1968\u20131972. A retrospective study","volume":"4","author":"Hird DW","year":"1975","journal-title":"J Med Primatol"},{"key":"e_1_2_6_14_1","unstructured":"ICH Guideline for industry.1994. Detection of toxicity to reproduction for medicinal products. FDA Website http:\/\/www.fda.gov\/cder\/Guidance\/s5a.pdf. Accessed July 11 2008."},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.164.5.2463"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1432-0436.1995.5920079.x"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1952.10483441"},{"key":"e_1_2_6_18_1","first-page":"735","article-title":"Evaluation of a surrogate antibody for safety testing. Toxicology of a murine anti\u2010CD11a antibody in mice","volume":"66","author":"Leach W","year":"2002","journal-title":"Toxicologist"},{"key":"e_1_2_6_19_1","first-page":"66","article-title":"Emerging biologic therapies in inflammatory bowel disease","volume":"4","author":"Lim WC","year":"2004","journal-title":"Rev Gastroenterol Disord"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20021569"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1071632"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2006.02837.x"},{"key":"e_1_2_6_23_1","first-page":"1880","article-title":"Four week toxicity study of a surrogate murine anti\u2010CD11a antibody in mice","volume":"72","author":"Mounho B","year":"2003","journal-title":"Toxicologist"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.8.2403"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.3109\/15419069409014200"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0015-0282(97)81388-X"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/ar.1092220210"},{"key":"e_1_2_6_28_1","unstructured":"TYSABRI (natalizumab) [prescribing information].2008. South San Francisco CA: Elan Pharmaceuticals Inc.; available atwww.tysabri.com."},{"key":"e_1_2_6_29_1","article-title":"Embryo\/Fetal development in cynomolgus monkeys exposed to natalizumab, an \u03b14 integrin inhibitor","author":"Wehner NG","year":"2009","journal-title":"Birth Defects Res B Dev Reprod Toxicol"},{"key":"e_1_2_6_30_1","article-title":"Effects of natalizumab, an \u03b14 integrin inhibitor, on the development of Hartley guinea pigs","author":"Wehner NG","year":"2009","journal-title":"Birth Defects Res B Dev Reprod Toxicol"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdrb.20191"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1080\/15476910902977381"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2006.11.001"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1242\/dev.121.2.549"}],"container-title":["Birth Defects Research Part B: Developmental and Reproductive Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fbdrb.20193","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bdrb.20193","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T02:38:28Z","timestamp":1697510308000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/bdrb.20193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3,12]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["10.1002\/bdrb.20193"],"URL":"https:\/\/doi.org\/10.1002\/bdrb.20193","archive":["Portico"],"relation":{},"ISSN":["1542-9733","1542-9741"],"issn-type":[{"value":"1542-9733","type":"print"},{"value":"1542-9741","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,3,12]]}}}